The device
One integrated device, 300+ diagnostic tests
The EVEDA HubX captures data across six vital organs using just five drops of blood and a urine sample. No venepuncture. No lab. Results in 15 minutes.
Country-level distribution partnerships with full regulatory support, training, and ongoing clinical quality assurance. TGA and Medsafe registered, with expansion pathways for new markets.
Pacific Island nations face the world's highest rates of diabetes and obesity, with populations dispersed across thousands of islands, chronic workforce shortages, and limited laboratory infrastructure. EVEDA was designed for exactly these conditions.
Fiji, Papua New Guinea, Samoa, Tonga, Vanuatu, Solomon Islands, and across Melanesia, Polynesia, and Micronesia. Purpose-built for remote island health settings.
Emerging market opportunities in rural and community health screening across the region. Distribution partnerships under development.
Portable, self-sufficient diagnostics for settings with infrastructure constraints. Expression of interest welcome from qualified distributors.
We support country-level distributors with everything needed to deploy, operate, and scale EVEDA in your market. From regulatory navigation to operator training and ongoing clinical quality assurance.
ARTG 346638 (Class IIb device system) and ARTG 342561 (Class I clinical software). Australian regulatory foundation for Oceania deployment.
Registered with New Zealand's medicines and medical devices safety authority under the Trans-Tasman framework.
EVEDA is actively pursuing additional regulatory pathways. Contact our international team to discuss registration requirements for your market.
The EVEDA HubX captures data across six vital organs using just five drops of blood and a urine sample. No venepuncture. No lab. Results in 15 minutes.